Table 1.
Demographics and Clinical Characteristics of the Study Population
| Total (N = 3316) | BNT162b2 (n = 1908) | mRNA-1273 (n = 1247) | Ad26.COV2.S (n = 161) | |
|---|---|---|---|---|
| Age, y | 43.7 ± 15.1 | 42.8 ± 15.2 | 45.1 ± 15.0 | 43.4 ± 14.5 |
| Sex | ||||
| Male | 919 (27.7) | 543 (28.5) | 331 (26.5) | 45 (28) |
| Female | 2378 (71.7) | 1355 (71.0) | 909 (72.9) | 114 (70.8) |
| Other | 19 (0.6) | 10 (0.5) | 7 (0.6) | 2 (1.2) |
| Race | ||||
| White | 3115 (93.9) | 1791 (93.9) | 1174 (94.1) | 150 (93.2) |
| Black/African American | 39 (1.2) | 23 (1.2) | 11 (0.9) | 5 (3.1) |
| Asian | 62 (1.9) | 33 (1.7) | 27 (2.1) | 2 (1.2) |
| Native Hawaiian/Pacific Islander | 2 (0.1) | 1 (0.1) | 1 (0.1) | 0 (0.0) |
| Multiple | 59 (1.8) | 39 (2.0) | 17 (1.4) | 3 (1.9) |
| Other | 39 (1.1) | 21 (1.1) | 17 (1.4) | 1 (0.6) |
| Hispanic | ||||
| Yes | 107 (3.2) | 66 (3.5) | 33 (2.6) | 8 (5.0) |
| No | 3198 (96.5) | 1836 (96.2) | 1209 (97.0) | 153 (95.0) |
| Unknown | 11 (0.3) | 6 (0.3) | 5 (0.4) | 0 (0.0) |
| BMI, kg/m2 | 26.1 ± 7.7 | 25.8 ± 8.4 | 26.5 ± 6.7 | 26.5 ± 6.4 |
| Current Smoker | ||||
| Yes | 69 (2.1) | 41 (2.1) | 24 (1.9) | 4 (2.5) |
| No | 3247 (97.9) | 1867 (97.9) | 1223 (98.1) | 157 (97.5) |
| Region | ||||
| Northeast | 784 (23.7) | 451 (23.7) | 292 (23.5) | 41 (25.5) |
| South | 996 (30.0) | 559 (29.3) | 394 (31.6) | 43 (26.7) |
| Midwest | 811 (24.5) | 494 (25.9) | 277 (22.2) | 40 (24.8) |
| West | 722 (21.8) | 402 (21.1) | 283 (22.7) | 37 (23.0) |
| Highest grade | ||||
| <12th grade | 76 (2.3) | 71 (3.7) | 5 (0.4) | 0 (0.0) |
| 12th grade or GED | 87 (2.6) | 61 (3.2) | 23 (1.8) | 3 (1.9) |
| Some college | 405 (12.2) | 202 (10.6) | 169 (13.6) | 34 (21.1) |
| College | 1339 (40.4) | 747 (39.2) | 525 (42.1) | 67 (41.6) |
| Graduate school | 1408 (42.5) | 826 (43.3) | 525 (42.1) | 57 (35.4) |
| Disease duration, y | 17.7 ± 12.4 | 17.3 ± 12.3 | 18.2 ± 12.6 | 17.5 ± 11.7 |
| 0-9 y | 956 (28.8) | 574 (30.1) | 332 (26.7) | 50 (31.1) |
| 10-19 y | 1154 (34.8) | 664 (34.8) | 439 (35.2) | 51 (31.7) |
| 20-29 y | 678 (20.5) | 386 (20.2) | 253 (20.3) | 39 (24.2) |
| 30-39 y | 289 (8.7) | 157 (8.2) | 122 (9.8) | 10 (6.2) |
| 40+ y | 238 (7.2) | 127 (6.7) | 100 (8.0) | 11 (6.8) |
| IBD hospitalization (ever) | ||||
| Yes | 2050 (61.8) | 1169 (61.3) | 775 (62.1) | 106 (65.8) |
| No | 1266 (38.2) | 739 (38.7) | 472 (37.9) | 55 (34.2) |
| IBD hospitalization (past 6 mo) | ||||
| Yes | 129 (3.9) | 69 (3.6) | 52 (4.2) | 8 (5.0) |
| No | 3187 (96.1) | 1839 (96.4) | 1195 (95.8) | 153 (95.0) |
| IBD activity 6 mo before vaccine | ||||
| Constantly active (daily sxs) | 189 (5.7) | 103 (5.4) | 79 (6.3) | 7 (4.3) |
| Often active (sxs most days) | 365 (11.0) | 190 (10.0) | 158 (12.7) | 17 (10.6) |
| Sometimes active (sxs 1-2d/wk) | 602 (18.1) | 319 (16.7) | 242 (19.4) | 41 (25.5) |
| Occasionally active (sxs 1-2 d/mo) | 526 (15.9) | 317 (16.6) | 185 (14.8) | 24 (14.9) |
| Rarely active (sxs on a few days) | 557 (16.8) | 328 (17.2) | 203 (16.3) | 26 (16.1) |
| Well/remission | 1077 (32.5) | 651 (34.1) | 380 (30.5) | 46 (28.6) |
| Oral/parenteral steroids | ||||
| Yes | 153 (4.6) | 93 (4.9) | 54 (4.3) | 6 (3.7) |
| No | 3163 (95.4) | 1815 (95.1) | 1193 (95.7) | 155 (96.3) |
| Oral budesonide | ||||
| Yes | 139 (4.2) | 80 (4.2) | 50 (4.0) | 9 (5.6) |
| No | 3177 (95.8) | 1828 (95.8) | 1197 (96.0) | 152 (94.4) |
| Oral mesalamine | ||||
| Yes | 622 (18.8) | 346 (18.1) | 246 (19.7) | 30 (18.6) |
| No | 2694 (81.2) | 1562 (81.9) | 1001 (80.3) | 131 (81.4) |
| Sulfasalazine | ||||
| Yes | 98 (3.0) | 58 (3.0) | 39 (3.1) | 1 (0.6) |
| No | 3218 (97.0) | 1850 (97.0) | 1208 (96.9) | 160 (99.4) |
| Thiopurine | ||||
| Yes | 554 (16.7) | 309 (16.2) | 220 (17.6) | 25 (15.5) |
| No | 2762 (83.3) | 1599 (83.8) | 1027 (82.4) | 136 (84.5) |
| Methotrexate | ||||
| Yes | 179 (5.4) | 114 (6.0) | 60 (4.8) | 5 (3.1) |
| No | 3137 (94.6) | 1794 (94.0) | 1187 (95.2) | 156 (96.9) |
| Infliximab | ||||
| Yes | 807 (24.3) | 482 (25.3) | 289 (23.2) | 36 (22.4) |
| No | 2509 (75.7) | 1426 (74.7) | 958 (76.8) | 125 (77.6) |
| Adalimumab | ||||
| Yes | 626 (18.9) | 376 (19.7) | 218 (17.5) | 32 (19.9) |
| No | 2690 (81.1) | 1532 (80.3) | 1029 (82.5) | 129 (80.1) |
| Certolizumab | ||||
| Yes | 57 (1.7) | 29 (1.5) | 25 (2.0) | 3 (1.9) |
| No | 3259 (98.3) | 1879 (98.5) | 1222 (98.0) | 158 (98.1) |
| Golimumab | ||||
| Yes | 25 (0.8) | 18 (0.9) | 6 (0.5) | 1 (0.6) |
| No | 3291 (99.2) | 1890 (99.1) | 1241 (99.5) | 160 (99.4) |
| Vedolizumab | ||||
| Yes | 402 (12.1) | 219 (11.5) | 163 (13.1) | 20 (12.4) |
| No | 2914 (87.9) | 1689 (88.5) | 1084 (86.9) | 141 (87.6) |
| Ustekinumab | ||||
| Yes | 489 (14.7) | 273 (14.3) | 195 (15.6) | 21 (13.0) |
| No | 2827 (85.3) | 1635 (85.7) | 1052 (84.4) | 140 (87.0) |
| Tofacitinib | ||||
| Yes | 59 (1.8) | 30 (1.6) | 25 (2.0) | 4 (2.5) |
| No | 3257 (98.2) | 1878 (98.4) | 1222 (98.0) | 157 (97.5) |
| Cyclosporine | ||||
| Yes | 2 (0.1) | 1 (0.1) | 1 (0.1) | 0 (0.0) |
| No | 3314 (99.9) | 1907 (99.9) | 1246 (99.9) | 161 (100.0) |
| Tacrolimus | ||||
| Yes | 15 (0.5) | 5 (0.3) | 6 (0.5) | 4 (2.5) |
| No | 3301 (99.5) | 1903 (99.7) | 1241 (99.5) | 157 (97.5) |
| COVID-19 infection prior to vaccine | ||||
| Yes | 160 (4.8) | 83 (4.4) | 67 (5.4) | 10 (6.2) |
| No | 3156 (95.2) | 1825 (95.6) | 1180 (94.6) | 151 (93.8) |
| COVID-19 infection since first vaccine | ||||
| Yes | 10 (0.3) | 7 (0.4) | 3 (0.2) | 0 (0.0) |
| No | 3306 (99.7) | 1901 (99.6) | 1244 (99.8) | 161 (100.0) |
Values are mean ± SD or n (%).
Abbreviations: Ad26.COV2.S, Johnson & Johnson; BMI, body mass index; BNT162b2, Pfizer-BioNTech; COVID-19, coronavirus disease 2019; d, day; IBD, inflammatory bowel disease; mo, month; mRNA-1273, NIH-Moderna; sxs, symptoms; wk, week.